May 10, 2017
(PRNewswire) — Bridge Therapeutics, Inc., an innovative development-stage specialty pharmaceutical company, announced that its CEO and Chief Scientific Officer Greg Sullivan, MD, presented at BioTrinity 2017 in London on Thursday, May 11. BioTrinity is Europe’s leading biopartnering and investment conference and the largest of its type in the UK. The conference, in its 11th year, draws attendees from approximately 30 countries and includes more than 1,000 delegates, dozens of exhibitors, and industry leaders from investment firms and global pharma.
Dr. Sullivan’s presentation to key investors and senior industry executives focused on the story of Bridge Therapeutics and its investigational drug compound BT-205, a unique combination of two synergistic chronic pain drugs—the partial-agonist opioid buprenorphine and the NSAID meloxicam—delivered in a state-of-the-art sublingual formulation.